NDAINJECTIONINJECTABLE
Approved
Mar 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
LIDOPEN (lidocaine hydrochloride) by CooperSurgical is 12. First approved in 1975.
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIDOPEN (lidocaine hydrochloride) is a local anesthetic injectable that stabilizes neuronal membranes by inhibiting ionic fluxes required for impulse initiation and conduction. It is used for local anesthetic procedures across multiple administration routes and patient populations. The drug works through membrane stabilization to produce rapid onset local anesthesia.
LOE Approaching
As a mature injectable with approaching loss of exclusivity, the LIDOPEN brand team is likely focused on retention and operational efficiency rather than growth initiatives.
Mechanism of Action
12.1 Mechanism of Action Lidocaine hydrochloride stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. 12.2 Pharmacodynamics Excessive blood levels may cause changes in cardiac output, total…
Worked on LIDOPEN at CooperSurgical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.